2. Search Result
Search Result
Pathways Recommended: NF-κB
Results for "

mmp,NF-κB

" in MedChemExpress (MCE) Product Catalog:

1548

Inhibitors & Agonists

9

Screening Libraries

8

Fluorescent Dye

24

Biochemical Assay Reagents

73

Peptides

4

MCE Kits

20

Inhibitory Antibodies

690

Natural
Products

93

Isotope-Labeled Compounds

7

Antibodies

2

Click Chemistry

16

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155998
    NF-κB-IN-11

    		NF-κB Inflammation/Immunology
    NF-κB-IN-11 (Compound 3i) is a NF-κB inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .
    NF-κB-IN-11
  • HY-144765
    NF-κB-IN-4
    1 Publications Verification

    		 NF-κB Apoptosis Neurological Disease Inflammation/Immunology
    NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
    NF-κB-IN-4
  • HY-138537
    NF-κB-IN-1
    3 Publications Verification

    		 IKK Cancer
    NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .
    NF-κB-IN-1
  • HY-126026
    NF-κB-IN-17

    		NF-κB Inflammation/Immunology
    NF-κB-IN-17 (Zinc5) is a NF-κB inhibitor. NF-κB-IN-17 inhibits TNF-α-induced NF-κB DNA binding activity in C2C12 cells .
    NF-κB-IN-17
  • HY-149838
    NF-κB-IN-9

    		NF-κB Cancer
    NF-κB-IN-9 is a nuclear factor kappa B (NF-κB) targeting sonosensitizer (λex/λem=489/628 nm). NF-κB-IN-9 exhibits strong inhibition on NF-κB signaling due to its two resveratrol units in one molecule. NF-κB-IN-9 has anti-tumor activity and shows remarkable sonocytotoxicity against cancer cells. NF-κB-IN-9 has biosafety in eenograft mice model.
    NF-κB-IN-9
  • HY-144744
    NF-κB-IN-3

    		NF-κB Cancer
    NF-κB-IN-3 (Compound 2) is a NF-κB inhibitor with an IC50 of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .
    NF-κB-IN-3
  • HY-170659
    NF-κB-IN-18

    		NF-κB Inflammation/Immunology
    NF-κB-IN-18 (Compound 5k) is an orally active NF-κB inhibitor. NF-κB-IN-18 inhibits phosphorylation of p65. NF-κB-IN-18 exhibits potent anti-inflammatory activity in Xylene-induced ear edema mice .
    NF-κB-IN-18
  • HY-162316
    NF-κB-IN-15

    		NF-κB Inflammation/Immunology
    NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) .
    NF-κB-IN-15
  • HY-149580
    NF-κB-IN-12

    		NF-κB Inflammation/Immunology
    NF-κB-IN-12 (compound 3h) is a potent NF-κB inhibitor, with an IC50 of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research .
    NF-κB-IN-12
  • HY-149351
    NF-κB-IN-10

    		NF-κB Cardiovascular Disease
    NF-κB-IN-10 (compound E1) is an NF-κB inhibitor that can improve heart failure by reducing oxidative stress and inflammation by regulating Nrf2/NF-κB signaling pathway. NF-κB-IN-10 inhibits LPS-induced NO production and expression of iNOS and COX-2 in RAW264.7 cells. NF-κB-IN-10 can be used in the research of cardiovascular diseases .
    NF-κB-IN-10
  • HY-N12283
    NF-κB-IN-13

    		NF-κB Inflammation/Immunology
    NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced NF-κB activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects .
    NF-κB-IN-13
  • HY-149248
    NF-κB-IN-8

    		NF-κB Inflammation/Immunology
    NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI) .
    NF-κB-IN-8
  • HY-142958
    NF-κB-IN-2

    		NF-κB Neurological Disease
    NF-κB-IN-2 inhibits TNF-α-induced canonical NF-κB signaling in PC-3 cells.
    NF-κB-IN-2
  • HY-172201
    NF-κB-IN-19

    		NF-κB Reactive Oxygen Species (ROS) Autophagy Apoptosis HIF/HIF Prolyl-Hydroxylase Akt STAT PI3K Inflammation/Immunology Cancer
    NF-κB-IN-19 (Compound 8) is an NF-κB inhibitor. NF-κB-IN-19 effectively induces DNA damage, promotes the generation of ROS, and induces autophagy and apoptosis through the NF-κB signaling pathway in tumor cells. In addition, NF-κB-IN-19 can inhibit the levels of VEGF and HIF-1α, and exert antiproliferative activity in tumor cells through the PI3K/AKT and STAT-3 pathways. NF-κB-IN-19 can effectively overcome cisplatin resistance and has anti-tumor activity .
    NF-κB-IN-19
  • HY-168482
    NF-κB/MAPK-IN-2

    		NF-κB p38 MAPK Cancer
    NF-κB/MAPK-IN-2 (compound 14) is a potent NF-κB and MAPK Inhibitor. NF-κB/MAPK-IN-2 decreases the protein expression of p-p65, p-IκB, p-p38, p-JNK, and p-ERK. NF-κB/MAPK-IN-2 reduces the LPS-induced release of TNF-α and IL-6. NF-κB/MAPK-IN-2 inhibits nuclear translocation of p65 and c-Fos. NF-κB/MAPK-IN-2 has the potential for the research of sepsis .
    NF-κB/MAPK-IN-2
  • HY-175833
    NF-κB-IN-20

    		NF-κB Keap1-Nrf2 Heme Oxygenase (HO) Interleukin Related TNF Receptor Reactive Oxygen Species (ROS) SOD Inflammation/Immunology
    NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI) .
    NF-κB-IN-20
  • HY-162004
    NF-κB-IN-14

    		NF-κB Toll-like Receptor (TLR) Inflammation/Immunology
    NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC50: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .
    NF-κB-IN-14
  • HY-158156
    NF-κB-IN-16

    		NF-κB Apoptosis Cancer
    NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .
    NF-κB-IN-16
  • HY-147972
    NF-κB/MAPK-IN-1

    		NF-κB p38 MAPK NO Synthase COX Inflammation/Immunology
    NF-κB/MAPK-IN-1 (compound 11a) is a potent inhibitor of NF-κB and MAPK pathway. NF-κB/MAPK-IN-1 shows inhibitory activity against NO production, with an IC50 of 6.96 µM. NF-κB/MAPK-IN-1 suppresses LPS-induced iNOS, COX-2, ERΚ and P38 signaling activation. NF-κB/MAPK-IN-1 can prevent LPS induced inflammatory response in macrophages. NF-κB/MAPK-IN-1 can be used for rheumatoid arthritis (RA) research .
    NF-κB/MAPK-IN-1
  • HY-147682
    NF-κB-IN-5

    		NF-κB Apoptosis Cancer
    NF-κB-IN-5 (compound 4d) is an orally active and potent NF-κB inhibitor by interacting directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines (HCT116, U87-MG, HepG2, BGC823, PC9), with IC50 values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM, respectively. NF-κB-IN-5 induces apoptosis in U87-MG tumor cell and cell cycle arrest in G0/G1 phase .
    NF-κB-IN-5
  • HY-147770
    NF-κB-IN-6

    		NF-κB Inflammation/Immunology
    NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent through the mechanism of decreasing the protein expressions of iNOS and COX-2 by suppressing NF-κB signaling pathway. NF-κB-IN-6 inhibits NO production in LPS-induced RAW264.7 cells with an IC50 of 23.1 μM .
    NF-κB-IN-6
  • HY-174138
    NF-κB degrader 1

    		NF-κB Inflammation/Immunology
    NF-κB degrader 1 (Compound MD-1) is a NF-κB1 p105 subunit degrader. NF-κB degrader 1 shows anti-inflammatory activity (IC50 for inhibiting TNF-α is 2.02 μM, and for inhibiting NO is 5.40 μM). NF-κB degrader 1 induces p105 degradation dependent on the Cullin-RING ligase (CRL) SCFBTCP, suppressing NF-κB transcriptional activity. NF-κB degrader 1 is promising for research of inflammation-related diseases .
    NF-κB degrader 1
  • HY-147836
    Akt/NF-κB/JNK-IN-1

    		Akt NF-κB JNK TNF Receptor COX Inflammation/Immunology
    Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC50 of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities .
    Akt/NF-κB/JNK-IN-1
  • HY-161520
    Glucocorticoid receptor/NF-κB modulator-1

    		Glucocorticoid Receptor NF-κB Inflammation/Immunology
    Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. Glucocorticoid receptor/NF-κB modulator-1 suppresses the degradation of glucocorticoid receptor (GR) mRNA and GR protein, inhibits the activation of NF-κB signaling pathway. Glucocorticoid receptor/NF-κB modulator-1 downregulates levels of NO, interleukin-6 and tumor necrosis factor-alpha (TNF-α). Glucocorticoid receptor/NF-κB modulator-1 ameliorates sepsis in mouse model .
    Glucocorticoid receptor/NF-κB modulator-1
  • HY-146058
    NF-κB/PON1-IN-1

    		NF-κB Reactive Oxygen Species (ROS) Cancer
    NF-κB/PON1-IN-1 (Compound 16) is a NF-κB/PON1 pathway inhibitor. NF-κB/PON1-IN-1 has antioxidant (IC50 = 45.76 µM) and hepatoprotective activities .
    NF-κB/PON1-IN-1
  • HY-168710
    TLR4/NF-κB-IN-1

    		Toll-like Receptor (TLR) NF-κB IKK Inflammation/Immunology
    TLR4/NF-κB-IN-1 (Compound 7x) is an orally available inhibitor that specifically targets the TLR4/NF-κB signaling pathway, offering anti-inflammatory effects and the ability to cross the blood-brain barrier. TLR4/NF-κB-IN-1 can reduce acute neuroinflammation in mice caused by LPS (HY-D1056) and downregulate the expression of TLR4, P-NF-κB and P-IκB-α proteins .
    TLR4/NF-κB-IN-1
  • HY-175227
    STAT3/NF-κB-IN-1

    		STAT NF-κB Apoptosis Caspase Bcl-2 Family Cancer
    STAT3/NF-κB-IN-1 is a potentSTAT3 and NF-κB inhibitor with IC50s of 5.86 (STAT3) and 4.22 μM (NF-κB) in 4T1 cells. STAT3/NF-κB-IN-1 is able to induce apoptosis via its upregulation on key apoptotic regulators; caspases-3/9, Bax and downregulation of Bcl-2. STAT3/NF-κB-IN-1 exerts considerable anticancer activity against breast cancer cell lines and reduces tumor volume in vivo. STAT3/NF-κB-IN-1 can be used for the study of breast cancer .
    STAT3/NF-κB-IN-1
  • HY-149496
    Akt/NF-κB/MAPK-IN-1

    		p38 MAPK ERK JNK Interleukin Related TNF Receptor NO Synthase COX Others
    Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways .
    Akt/NF-κB/MAPK-IN-1
  • HY-173488
    NF-κB/HIF-1α-IN-1

    		NF-κB HIF/HIF Prolyl-Hydroxylase Keap1-Nrf2 Cancer
    NF-κB/HIF-1α-IN-1 (compound 9c) is a potent blocker of the NF-κB activation pathway and demonstrates selective anti-fibrotic activity. NF-κB/HIF-1α-IN-1 shows no significant cytotoxicity in NCI tumor cell lines. In rat models. NF-κB/HIF-1α-IN-1 has been shown to effectively ameliorate liver fibrosis by inhibiting the expression levels of NF-κB and HIF-1α, while simultaneously inducing the activation of Nrf2 .
    NF-κB/HIF-1α-IN-1
  • HY-142963
    TLR4/NF-κB/MAPK-IN-1

    		NF-κB p38 MAPK Toll-like Receptor (TLR) Neurological Disease Inflammation/Immunology
    TLR4/NF-κB/MAPK-IN-1 is a new type of antineuroinflammatory agent by suppressing TLR4/NF-kB/MAPK pathways.
    TLR4/NF-κB/MAPK-IN-1
  • HY-133987
    AP-1/NF-κB activation inhibitor 1
    2 Publications Verification

    		 NF-κB Inflammation/Immunology
    AP-1/NF-κB activation inhibitor 1 is a potent AP-1 and NF-κB mediated transcriptional activation inhibitor (IC50=1 μM), without blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells .
    AP-1/NF-κB activation inhibitor 1
  • HY-131385
    KB02-COOH

    		Ligands for E3 Ligase Cancer
    KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610) .
    KB02-COOH
  • HY-170506
    KB-208

    		Others Inflammation/Immunology
    KB-208 is a phagocytosis inhibitor that improves immune thrombocytopenia (ITP) in mouse models at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum toxicity biomarkers. KB-208 can be used in immunology research .
    KB-208
  • HY-W681659
    Flutoprazepam

    KB-509

    		 GABA Receptor Neurological Disease
    Flutoprazepam (KB-509), a benzodiazepine drug, possesses anticonflict effect. Flutoprazepam (KB-509) prevents maximal electroshock, pentetrazol, and strychnine-induced convulsions in mice .
    Flutoprazepam
  • HY-175542
    KB-15

    		STAT Apoptosis Reactive Oxygen Species (ROS) PARP Cancer
    KB-15 is a STAT3 inhibitor. KB-15 exhibits potent anti-proliferative activity against AGS gastric cancer cells (IC50 = 0.29 μM) and BGC-823 gastric cancer cells (IC50 = 0.65 μM). KB-15 exerts anti-tumor effects by inhibiting STAT3 phosphorylation, downregulating HO-1 expression, and promoting intracellular ROS accumulation. KB-15 induces G0/G1 phase cell cycle arrest and apoptosis, as well as suppresses colony formation and migration of gastric cancer cells. KB-15 demonstrates excellent anti-tumor efficacy in BGC-823 subcutaneous xenograft model. KB-15 can be used for the study of gastric cancer .
    KB-15
  • HY-P99135
    Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3)

    		MHC Inflammation/Immunology
    Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) is a mouse-derived IgG2b antibody inhibitor, targeting to mouse MHC Class I (H-2Kb). Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) reacts with the mouse H-2Kb, H-2Kk, H-2Kq, H-2Kr, H-2ks MHC class I alloantigens and not H-2Kd. Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) can block MHC Class I. Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) can be used for immunology research .
    Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3)
  • HY-129610
    KB02-SLF

    		PROTACs FKBP Cancer
    KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .
    KB02-SLF
  • HY-137478B
    KB-0742 hydrochloride

    		CDK Cancer
    KB-0742 hydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 hydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 hydrochloride has potent anti-tumor activity .
    KB-0742 hydrochloride
  • HY-137478
    KB-0742
    2 Publications Verification

    		 CDK Cancer
    KB-0742 is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .
    KB-0742
  • HY-137478A
    KB-0742 dihydrochloride
    2 Publications Verification

    		 CDK Cancer
    KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .
    KB-0742 dihydrochloride
  • HY-136741
    BOT-64
    1 Publications Verification

    		 IKK Inflammation/Immunology
    BOT-64 is an inhibitory κB (IκB) kinase β (IKKβ) inhibitor with an IC50 of 1 µM. BOT-64 blocks lipopolysaccharide-induced nuclear factor-κB activation and nuclear factor-κB-regulated inflammatory gene transcription .
    BOT-64
  • HY-176535
    KB-0118

    BBC0115

    		 Epigenetic Reader Domain Interleukin Related STAT Inflammation/Immunology
    KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.
    KB-0118
  • HY-19081
    KB-5246

    		Bacterial Antibiotic Infection
    KB-5246 is a tetracyclic quinolone and displays antibacterial activities.
    KB-5246
  • HY-10257
    BAY 11-7085
    40+ Cited Publications

    BAY 11-7083

    		 NF-κB Ferroptosis Apoptosis Cancer
    BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC50 of 10 μM .
    BAY 11-7085
  • HY-129917
    KB02-JQ1
    4 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1 .
    KB02-JQ1
  • HY-176389
    KB02-amide-PEG2-C2-acid

    		E3 Ligase Ligand-Linker Conjugates Cancer
    KB02-amide-PEG2-C2-acid is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as KB02-SLF (HY-129610) .
    KB02-amide-PEG2-C2-acid
  • HY-13982
    JSH-23
    115+ Cited Publications

    		 NF-κB Metabolic Disease Inflammation/Immunology Cancer
    JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation .
    JSH-23
  • HY-N0277
    Aconine
    2 Publications Verification

    Jesaconine

    		 NF-κB Inflammation/Immunology Cancer
    Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.
    Aconine
  • HY-162092
    Multi-target Pt

    		NF-κB IKK Cancer
    Multi-target Pt (IV), an antitumor agent, suppresses the IKKβ phosphorylation, IκBα phosphorylation and NF-κB p65 phosphorylation and nuclear translocation, leading to blocked the NF-kB signal pathway .
    Multi-target Pt
  • HY-P1489
    OVA Peptide(257-264)
    10+ Cited Publications

    		 MHC Inflammation/Immunology
    OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
    OVA Peptide(257-264)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: